Patents by Inventor Chengyin Min

Chengyin Min has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof
    Patent number: 11666568
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 6, 2023
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Nathan Moore, Chengyin Min
  • Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
    Patent number: 11324744
    Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: May 10, 2022
    Assignee: Acetylon Pharmaceuticals Inc.
    Inventors: Simon Steward Jones, Chengyin Min, Steven Norman Quayle
  • PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A BCL-2 INHIBITOR AND METHODS OF USE THEREOF
    Publication number: 20190262337
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Application
    Filed: November 3, 2017
    Publication date: August 29, 2019
    Inventors: Nathan MOORE, Chengyin MIN
  • METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES
    Publication number: 20180036306
    Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also provided herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 8, 2018
    Inventors: Simon Steward Jones, Chengyin Min, Steven Norman Quayle
  • Treatment of leukemia with histone deacetylase inhibitors
    Patent number: 9833466
    Abstract: Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: December 5, 2017
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Simon S. Jones, Chengyin Min, Min Yang, David Lee Tamang
  • TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS
    Publication number: 20160030458
    Abstract: Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.
    Type: Application
    Filed: July 6, 2015
    Publication date: February 4, 2016
    Inventors: Simon S. Jones, Chengyin Min, Min Yang, David Lee Tamang
  • METHODS OF PREDICTING PROGNOSIS IN CANCER
    Publication number: 20140302042
    Abstract: A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 9, 2014
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Lynda Chin, Kenneth L. Scott, Papia Ghosh, Kunal Rai, Chengyin Min